Business Wire

Ganymed Robotics Announces Appointment of Seasoned Leadership Team to Bring to Market Its Next Generation Surgical Technology

3.10.2023 09:30:00 EEST | Business Wire | Press release

Share

Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, is happy to announce a series of senior leadership appointments to drive the company’s growth as it prepares for industrialization and commercial launch. The firm has appointed 5 seasoned executives to lead strategic and operational developments across all key functions, ranging from product development to regulatory and market access, finance, human resources and legal. Former companies include ZimmerBiomet, Alphatec, EOS Imaging, Corwave, Beckton Dickinson, Robocath, Médecins Sans Frontières.

The composition of the new Executive Committee exhibits strong expertise in both launching innovative medical devices and scaling medtech companies, as well as gender parity. It is composed of 8 members : Sophie Cahen, CEO and co-founder, Silvère Lucquin, Chief Operating Officer, and Michel Vernizeau, VP R&D, and 5 seasoned new members: Lukas Vancura as VP Product Marketing, Clémentine Liard as VP Quality Assurance and Regulatory Affairs (QARA), Sandra Demol as Human Resources Director, Julien Puaux as VP Finance and Juliette Loget as General Counsel. These additions to the Executive Committee reflect Ganymed’s continued attractiveness for talents of all seniority, and its commitment to bringing its game-changing arthroplasty robot into operating rooms as quickly as possible.

“I am delighted to partner with such talented senior executives who bring to the company their impressive experience and recognized expertise, as we accelerate the development of our revolutionary patented technology platform and prepare for industrialization and launch of our first surgical robotic assistant for knee arthroplasty,” says Sophie Cahen. “The arrival of the leadership team’s newest members is a testimony of the swift growth that Ganymed accomplished over the past 18 months, both on the scientific and operational fronts, and speaks to a team united by a profound sense of shared purpose.”

Ganymed Robotics’ ambition is to democratize access to quality care in hard tissue surgery. The company aims to secure and standardize a complex surgical gesture, so that each patient gets the right, personalized care. The first application is a co-manipulated surgical robotic assistant for total knee arthroplasty (TKA). It has developed a proprietary technology platform built around two disruptive innovations: contactless localization of the bones and human-machine collaborative movement.

Over the past 18 months, Ganymed reached several major milestones, attesting of its ability to efficiently implement its growth strategy: it completed a 36 M€ Series B fundraising round with a high-profile group of healthcare investors, welcomed two world renowned independent members on its Board of Directors, Michel Therin et Mike Lobinsky, doubled the size of its team across all functions to reach 40 persons today, secured strategic partnerships, moved forward with regulatory and marketing developments, won new national and international innovation awards, and ran successful pre-clinical tests. With the arrival of high-profile senior executives on its leadership team, Ganymed is ideally positioned to successfully accelerate the execution of its strategic, industrial, and operational development plan.

About Ganymed Robotics

Ganymed Robotics is a medical device company founded in 2018, developing the next generation of robotic assistance technologies for orthopedic surgery. The company’s mission is to improve patient outcome, surgeon experience, and overall efficiency of care delivery for its target indications. Based in Paris, Ganymed Robotics currently employs 40 people who develop a proprietary technology platform combining computer vision, a branch of artificial intelligence, and mechatronics, in close collaboration with world-class clinicians and advisors. The first application is a robotic surgical assistant for knee arthroplasties, a common and fast-growing intervention associated with high dissatisfaction rates of above 20%. Ganymed Robotics intends to progressively deploy its technology to address several other orthopedics indications. Ganymed Robotics won national and international innovation awards, such as I-Nov, I-Lab, French Tech DeepNum20, French Tech Emergence, Deep Tech Pioneer, EIT Health, Wilco, EIC Accelerator. For more information: www.ganymedrobotics.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Strategies & Image (S&I)
Anne Rein
+33 6 03 35 92 05
anne.rein@strategiesimage.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

INSEAD Launches Immersive AI Cases as Its AI-Powered Learning Portfolio Passes 40 Experiences17.9.2026 12:00:00 EEST | Press release

INSEAD, The Business School for the World, today announced two milestones inAI-enabled learning: the commercial launch of its firstImmersive AI Cases via INSEAD Publishing and the expansion of its Immersive Learning portfolio to reach over 40 AI-powered learning experiences in the INSEAD classroom. Together, these developments mark an important milestone in INSEAD’s vision to translate AI-enabled learning into scalable educational offerings for educators and learners worldwide. They also demonstrate the growing adoption of immersive learning across the school and represent a key step in advancing the ambitions of IN:AI, INSEAD’s initiative to harness AI to transform business education and prepare leaders for an AI-enabled world. Francisco Veloso, Dean of INSEAD, said: “The future of management education will not be about choosing between human expertise and AI, but about bringing the two together in ways that deepen learning and strengthen judgement. We are putting this principle into

LTM Honoured with Avasant Digital Masters Award 202617.9.2026 12:00:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced that it has been recognized with the Digital Masters Award 2026 in the Innovator category by Avasant, a leading management consulting firm. The award recognizes LTM's commitment to innovation, excellence, and its ability to drive transformative business outcomes for clients through its portfolio of AI-powered offerings. The award was presented during the Digital Masters Awards Ceremony at Partner Connect 2026 in Los Angeles. LTM was among the 18 service providers shortlisted from a field of over 76 global technology service providers assessed by Avasant for this year's Digital Masters Awards. This recognition reflects LTM's strong leadership, domain expertise, and continued contribution to delivering exceptional value for clients globally. "This recognition reflects our focus on helping clients leverage AI to accelerate transformation, create measurable business value, and stay ahead in a rapidly e

IQM to Deliver Its First Quantum Computer in South America to Brazil’s Eldorado Research Institute17.9.2026 10:43:00 EEST | Press release

IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced a purchase agreement with the Eldorado Research Institute to deploy its first quantum computer in South America, marking IQM's entry into the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917582765/en/ IQM to deliver its first quantum computer in South America to Brazil’s Eldorado Research Institute The IQM Spark quantum computer will be installed at Eldorado's Campinas headquarters, about 100km northwest of São Paulo, in the first quarter of 2027, giving researchers, engineers, universities and industry partners direct access to quantum computers. The agreement also includes remote access to IQM's 54-qubit cloud-based system in Europe, allowing Brazilian teams to develop applications on hardware they own and then move to larger-scale quantum workloads when a problem requires it. “Brazil has the talent, the

Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 09:00:00 EEST | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in children and adolescents with neurological conditions, including CP. This condition is associated with muscle tightness that can severely restrict physical movement, daily functioning, and personal autonomy. Among children and youth, CP stands as a primary driver of this symptom and remains the most prevalent childhood motor disability,

Mediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable Care17.9.2026 09:00:00 EEST | Press release

The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives that can improve care for people living with haemoglobinopathies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916107487/en/ Adam Plich, Co-Founder and CEO, Avanzanite Bioscience. Avanzanite enabled the establishment of the Network in recognition of both the considerable expertise that already exists across the Mediterranean and the persistent gaps that remain in access to specialist care, sustainable blood supplies, treatment advances and evidence-based inn

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye